TP53 and dedifferentiated liposarcoma: The overexpression of MDM2 in DDLPS is linked with worse prognosis and poor response to chemotherapy and so MDM2-p53 interaction has garnered interest as a therapeutic target for DDLPS and other malignancies [24].